Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,040.90 -39.46 (-3.65%)

Streaming Delayed Price Updated: 3:10 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Top S&P500 movers in Monday's session ↗

Today 15:05 EST

Via Chartmill

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

Today 14:38 EST

Via MarketBeat

Topics Artificial Intelligence Death

Bank of America Issues 2026 'Priced for Perfection' Warning: Why the S&P 500 Faces a High-Stakes 'Air Pocket'

Today 14:14 EST

As the financial world rings in 2026, a sobering forecast from one of Wall Street’s most influential institutions has sent a ripple of caution through the markets. Bank of America (NYSE: BAC) Global...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’ ↗

Today 7:27 EST

Via Stocktwits

MarketBeat Week in Review – 12/29 - 01/02 ↗

January 03, 2026

Via MarketBeat

Priced for Perfection: Bank of America Issues Stark Warning on S&P 500 Valuation for 2026

Today 14:14 EST

As the calendar turns to 2026, the euphoria that propelled the stock market through three consecutive years of double-digit gains is facing a sobering reality check. Bank of America (NYSE: BAC) has...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever ↗

Today 10:35 EST

Via MarketBeat

Eli Lilly: Strength Meets GLP‑1 Access Momentum ↗

Today 10:00 EST

Eli Lilly's stock remains robust at $1,080.36 amid positive market developments, strong GLP-1 access momentum, and heightened investor interest ahead of key earnings announcements.

Via Talk Markets

Is It Time to Dump Your Shares of Eli Lilly? ↗

Today 9:20 EST

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Via The Motley Fool

January 04, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

4 Stocks to Buy in January That Could Join Nvidia in the $1 Trillion Club by 2030 ↗

January 04, 2026

Visa, ExxonMobil, Oracle, and Netflix have multi-year compounding potential for patient investors.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: These Will Be the Biggest Stock Splits for 2026 ↗

January 03, 2026

Plenty of well-known companies seem ripe for stock splits -- though you shouldn't really care.

Via The Motley Fool

The Great 2026 Rebalancing: Institutional Giants Pivot from AI Hype to Industrial Execution

January 02, 2026

As the opening bell rang for the first trading session of 2026, the financial world witnessed the commencement of what analysts are calling "The Great Rebalancing." Institutional fund managers,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth

January 02, 2026

As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated...

Via MarketMinute

Topics Artificial Intelligence Economy

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

S&P 500 Tests Critical Support Levels as 2026 Kicks Off Under Technical Pressure

January 02, 2026

The S&P 500 (INDEXSP:.INX) entered the new year on a tenuous footing, grappling with a rare four-session losing streak that capped off an otherwise stellar 2025. After finishing the final trading day...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today ↗

January 02, 2026

Via Benzinga

Alphabet’s Golden Year: Inside the 2025 Rally and the Future of the AI Giant

January 02, 2026

As we enter 2026, the narrative surrounding the world’s most dominant information gateway has shifted from one of existential threat to unprecedented strength. Alphabet Inc. (NASDAQ: GOOGL / GOOG) has...

Via PredictStreet

Topics Artificial Intelligence Initial Public Offering

2 S&P 500 Stocks with Impressive Fundamentals and 1 We Avoid

January 01, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...

Via TokenRing AI

Topics Artificial Intelligence

The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery

January 01, 2026

The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...

Via TokenRing AI

Topics Artificial Intelligence

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

Navigating the Neutral Rate: Wall Street's 2026 Outlook Forecasts Growth Amidst AI Maturity

January 01, 2026

As the opening bell prepares to ring for the first time in 2026, the American investor finds themselves at a unique crossroads of technological maturation and economic normalization. Following a robust...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗

January 01, 2026

These two companies have very different risk-reward profiles.

Via The Motley Fool

Topics Artificial Intelligence

Where Will Pfizer Be in 5 Years? ↗

December 31, 2025

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.

Via The Motley Fool

Topics Intellectual Property

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗

December 31, 2025

Via MarketBeat

So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO. ↗

December 31, 2025

Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.